Scholarlink

<p>Hepatocellular carcinoma (HCC) is characterized by high invasiveness and metastatic potential, leading to poor prognosis. Therefore, understanding the molecular mechanisms underlying HCC invasion and metastasis is essential for developing effective therapeutic strategies. This study investigates the role of ZMYM3 in HCC invasion and metastasis. Analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, along with immunohistochemistry, revealed that ZMYM3 is upregulated in HCC tissues and associated with recurrence and poor prognosis. Single-cell sequencing data indicated higher ZMYM3 expression in portal vein tumor thrombus compared to primary lesions, suggesting its involvement in metastasis. Functional assays demonstrated that ZMYM3 enhances HCC cell proliferation, invasion, and metastasis. RNA sequencing identified that ZMYM3 promotes invadopodia formation and epithelial-mesenchymal transition (EMT) in HCC cells. Further chromatin immunoprecipitation sequencing and mechanistic studies showed that ZMYM3 directly binds to the promoter of CTTN, a key gene regulating invadopodia formation, thereby increasing its expression. This upregulation contributes to the enhanced invasive and metastatic capabilities of HCC cells. Our findings identify ZMYM3 overexpression as a predictor of high recurrence risk and poor prognosis in HCC patients. Mechanistically, ZMYM3 promotes invadopodia formation primarily through the upregulation of CTTN, thereby augmenting the invasive and metastatic potential of HCC cells. These results highlight the critical role of ZMYM3 in HCC progression and metastasis.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcriptional factor ZMYM3 promotes hepatocellular carcinoma metastasis by upregulating CTTN and inducing invadopodia formation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Fuling Zeng,
  • Zihua Zhang,
  • Tingting Hu,
  • Xin Xia,
  • Da-Lin Lu,
  • Chen Qu,
  • Lu He

摘要

Hepatocellular carcinoma (HCC) is characterized by high invasiveness and metastatic potential, leading to poor prognosis. Therefore, understanding the molecular mechanisms underlying HCC invasion and metastasis is essential for developing effective therapeutic strategies. This study investigates the role of ZMYM3 in HCC invasion and metastasis. Analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, along with immunohistochemistry, revealed that ZMYM3 is upregulated in HCC tissues and associated with recurrence and poor prognosis. Single-cell sequencing data indicated higher ZMYM3 expression in portal vein tumor thrombus compared to primary lesions, suggesting its involvement in metastasis. Functional assays demonstrated that ZMYM3 enhances HCC cell proliferation, invasion, and metastasis. RNA sequencing identified that ZMYM3 promotes invadopodia formation and epithelial-mesenchymal transition (EMT) in HCC cells. Further chromatin immunoprecipitation sequencing and mechanistic studies showed that ZMYM3 directly binds to the promoter of CTTN, a key gene regulating invadopodia formation, thereby increasing its expression. This upregulation contributes to the enhanced invasive and metastatic capabilities of HCC cells. Our findings identify ZMYM3 overexpression as a predictor of high recurrence risk and poor prognosis in HCC patients. Mechanistically, ZMYM3 promotes invadopodia formation primarily through the upregulation of CTTN, thereby augmenting the invasive and metastatic potential of HCC cells. These results highlight the critical role of ZMYM3 in HCC progression and metastasis.